189 related articles for article (PubMed ID: 30618743)
1. Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool.
Bao XY; Zheng Q; Tong Q; Zhu PC; Zhuang Z; Zheng GQ; Wang Y
Front Pharmacol; 2018; 9():1445. PubMed ID: 30618743
[No Abstract] [Full Text] [Related]
2. A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury.
Zheng Q; Zhu JZ; Bao XY; Zhu PC; Tong Q; Huang YY; Zhang QH; Zhang KJ; Zheng GQ; Wang Y
Front Physiol; 2018; 9():795. PubMed ID: 30018562
[TBL] [Abstract][Full Text] [Related]
3. Ligustrazine Exerts Cardioprotection in Animal Models of Myocardial Ischemia/Reperfusion Injury: Preclinical Evidence and Possible Mechanisms.
Zheng Q; Huang YY; Zhu PC; Tong Q; Bao XY; Zhang QH; Zheng GQ; Wang Y
Front Pharmacol; 2018; 9():729. PubMed ID: 30090062
[TBL] [Abstract][Full Text] [Related]
4. Ginsenoside Rb1 for Myocardial Ischemia/Reperfusion Injury: Preclinical Evidence and Possible Mechanisms.
Zheng Q; Bao XY; Zhu PC; Tong Q; Zheng GQ; Wang Y
Oxid Med Cell Longev; 2017; 2017():6313625. PubMed ID: 29430282
[TBL] [Abstract][Full Text] [Related]
5. Notoginsenoside R1 for Organs Ischemia/Reperfusion Injury: A Preclinical Systematic Review.
Tong Q; Zhu PC; Zhuang Z; Deng LH; Wang ZH; Zeng H; Zheng GQ; Wang Y
Front Pharmacol; 2019; 10():1204. PubMed ID: 31680976
[TBL] [Abstract][Full Text] [Related]
6. Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms.
Zhu PC; Shen J; Qian RY; Xu J; Liu C; Hu WM; Zhang Y; Lv LC
Front Pharmacol; 2023; 14():1165212. PubMed ID: 37261285
[No Abstract] [Full Text] [Related]
7. Ginkgolide B for Myocardial Ischemia/Reperfusion Injury: A Preclinical Systematic Review and Meta-Analysis.
Zhu PC; Tong Q; Zhuang Z; Wang ZH; Deng LH; Zheng GQ; Wang Y
Front Physiol; 2019; 10():1292. PubMed ID: 31681006
[TBL] [Abstract][Full Text] [Related]
8. Fasudil, a Rho-Kinase Inhibitor, Exerts Cardioprotective Function in Animal Models of Myocardial Ischemia/Reperfusion Injury: A Meta-Analysis and Review of Preclinical Evidence and Possible Mechanisms.
Huang YY; Wu JM; Su T; Zhang SY; Lin XJ
Front Pharmacol; 2018; 9():1083. PubMed ID: 30327600
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation.
Yin Y; Guan Y; Duan J; Wei G; Zhu Y; Quan W; Guo C; Zhou D; Wang Y; Xi M; Wen A
Eur J Pharmacol; 2013 Jan; 699(1-3):219-26. PubMed ID: 23200898
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective effects of curcumin against myocardial I/R injury: A systematic review and meta-analysis of preclinical and clinical studies.
Li T; Jin J; Pu F; Bai Y; Chen Y; Li Y; Wang X
Front Pharmacol; 2023; 14():1111459. PubMed ID: 36969839
[No Abstract] [Full Text] [Related]
11. Pre-clinical Evidence: Berberine as a Promising Cardioprotective Candidate for Myocardial Ischemia/Reperfusion Injury, a Systematic Review, and Meta-Analysis.
Chen C; Lin Q; Zhu XY; Xia J; Mao T; Chi T; Wan J; Lu JJ; Li Y; Cui J; Liu J; Cui XY; Zhang J; Zhou K; Li D
Front Cardiovasc Med; 2021; 8():646306. PubMed ID: 34124190
[No Abstract] [Full Text] [Related]
12. Preclinical Evidence and Possible Mechanisms of
Li Y; Cai M; Mao GX; Shu QF; Liu XB; Liu XL
Front Pharmacol; 2021; 12():736198. PubMed ID: 34803686
[No Abstract] [Full Text] [Related]
13. Danshensu accelerates angiogenesis after myocardial infarction in rats and promotes the functions of endothelial progenitor cells through SDF-1α/CXCR4 axis.
Yin Y; Duan J; Guo C; Wei G; Wang Y; Guan Y; Mu F; Yao M; Xi M; Wen A
Eur J Pharmacol; 2017 Nov; 814():274-282. PubMed ID: 28864209
[TBL] [Abstract][Full Text] [Related]
14. Danshensu protects against ischemia/reperfusion injury and inhibits the apoptosis of H9c2 cells by reducing the calcium overload through the p-JNK-NF-κB-TRPC6 pathway.
Meng Y; Li WZ; Shi YW; Zhou BF; Ma R; Li WP
Int J Mol Med; 2016 Jan; 37(1):258-66. PubMed ID: 26718129
[TBL] [Abstract][Full Text] [Related]
15. A novel Danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways.
Cui G; Shan L; Hung M; Lei S; Choi I; Zhang Z; Yu P; Hoi P; Wang Y; Lee SM
Int J Cardiol; 2013 Sep; 168(2):1349-59. PubMed ID: 23290949
[TBL] [Abstract][Full Text] [Related]
16. Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling.
Yu J; Wang L; Akinyi M; Li Y; Duan Z; Zhu Y; Fan G
Int J Clin Exp Med; 2015; 8(9):14793-804. PubMed ID: 26628961
[TBL] [Abstract][Full Text] [Related]
17. Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy.
Wu S; Chang G; Gao L; Jiang D; Wang L; Li G; Luo X; Qin S; Guo X; Zhang D
J Mol Med (Berl); 2018 Aug; 96(8):791-806. PubMed ID: 29955901
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats.
Tang Y; Wang M; Le X; Meng J; Huang L; Yu P; Chen J; Wu P
Phytomedicine; 2011 Sep; 18(12):1024-30. PubMed ID: 21665454
[TBL] [Abstract][Full Text] [Related]
19. Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling.
Fan G; Yu J; Asare PF; Wang L; Zhang H; Zhang B; Zhu Y; Gao X
J Cell Mol Med; 2016 Oct; 20(10):1908-19. PubMed ID: 27385290
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Effect of Danshensu against Ischemic/Reperfusion Injury via c-Subunit of ATP Synthase Inhibition.
Gao Q; Zhao J; Fan Z; Bao J; Sun D; Li H; Sun C; Jiang X
Evid Based Complement Alternat Med; 2017; 2017():7986184. PubMed ID: 29250127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
